
Opinion|Videos|May 7, 2024
Highlighting the Available CDK4/6 Inhibitors
Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
American Regent Recalls 3 Epinephrine Injection Lots Over Particulate Matter, Sterility Concerns
2
Building a Strong Financial Foundation: 5 Pillars Every Pharmacist Needs Before Optimizing Their Financial Plan
3
In-Hospital Dapagliflozin Speeds Decongestion in Heart Failure
4
CKD Outcome Set Elevates Patient-Reported Measures
5





































































































